Search

131 Result(s)
Sort by

clinical_collaboration_with_Mirati

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Maria Weber

Maria Weber

Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.
Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Building blocks of our future

Building blocks of our future

Our global investment projects are the building blocks for improved healthcare and sustainability
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Martin Stefanic

Martin Stefanic

Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Trailr2-cdh17-antibody-phase1-trial

Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
clinical-collaboration-with-Amgen

clinical-collaboration-with-Amgen

Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Outlook for Partnering in Animal Health 2024

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.